Gary Raskob to Drug Therapy, Combination
This is a "connection" page, showing publications Gary Raskob has written about Drug Therapy, Combination.
Connection Strength
0.216
-
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost. 2013 Jul; 11(7):1287-94.
Score: 0.104
-
Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood. 1995 Jun 01; 85(11):3034-9.
Score: 0.030
-
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 04 05; 366(14):1287-97.
Score: 0.024
-
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012 Jan 14; 379(9811):123-9.
Score: 0.023
-
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):454S-545S.
Score: 0.018
-
Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1994 Oct 01; 74(7):657-61.
Score: 0.007
-
Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. 1992 Aug; 152(8):1589-95.
Score: 0.006
-
Prophylaxis of venous thromboembolism. An overview. Chest. 1986 May; 89(5 Suppl):374S-383S.
Score: 0.004